Nordic Issuing

Ongoing case

Saniona AB

Back to all cases

Saniona AB

6 Apr - 20 Apr 2021Warrant exercise TO 3

Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world.

The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for the rare diseases Prader-Willi syndrome and hypothalamic obesity. Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead candidate SAN711 entering Phase 1 studies for rare neuropathic disorders. Saniona intends to develop and commercialize its rare disease products internally. The company has out-licensed other programs, which may provide future supplemental revenue. Saniona is based in Copenhagen, Denmark and Boston, Mass., U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION)

Read more at the Company's website

The offer in summary

Terms: One (1) warrant of series TO 3 will give the holder the right to subscribe for one (1) new share in Saniona AB

Subscription period: April 2021

Number of warrants series TO 3: 1 479 742

Subscription price: 70% of the volume weighted average price during 17 March 2021 - 30 March 2021



Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.